Clinical trial
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444
Study timeline
Study start (actual)2021-09-07Date precision: day
Registry last updated2026-09-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Bladder Carcinomaunresolved
Ureter Carcinomaunresolved
Renal Pelvis Carcinomaunresolved
Non-small Cell Lung Cancerunresolved
Invasive Breast Carcinomaunresolved
Cutaneous Melanomaunresolved
Esophageal Carcinomaunresolved
Gastroesophageal Junction Carcinomaunresolved
Gastric Adenocarcinomaunresolved
Pancreatic Adenocarcinomaunresolved
Epithelial Ovarian Carcinomaunresolved
Fallopian Tube Carcinomaunresolved
Endometrial Carcinomaunresolved
Renal Cell Carcinomaunresolved
Rectal Adenocarcinomaunresolved
Colon Adenocarcinomaunresolved
Interventions
Guardant RevealDIAGNOSTIC_TEST
Sponsors & collaborators
Guardant Health, Inc.lead sponsor
Mapped research locations
MadridSpain3BarcelonaSpain3New YorkNew York, United States1BostonMassachusetts, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1San AntonioTexas, United States1ParisFrance1ClevelandOhio, United States1BirminghamAlabama, United States1CincinnatiOhio, United States1AuroraColorado, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05059444 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.